IDEX Corporation — Q1 2023 Form 10-Q
Business context and period. Unaudited results for the three months ended March 31, 2023, compared with the same 2022 period. IDEX manufactures application-specific products across Fluid & Metering Technologies (FMT), Health & Science Technologies (HST), and Fire & Safety/Diversified Products (FSDP).
Financial performance
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Net sales | $845.4 million | $751.1 million | +13%; organic sales +6% |
| Gross profit / margin | $382.5 million / 45.2% | $342.5 million / 45.6% | Profit +12%; margin -40 bps |
| Operating income | $192.3 million | $187.6 million | +3% |
| Net income attributable to IDEX | $139.8 million | $140.0 million | Approximately flat |
| Diluted EPS | $1.84 | $1.83 | +1% |
| Adjusted EBITDA / margin | $229.8 million / 27.2% | $214.7 million / 28.6% | +7%; margin -140 bps |
| Operating cash flow | $147.9 million | $79.7 million | +86% |
| Free cash flow | $121.3 million | $63.6 million | +91% |
Reported sales growth included a 9% contribution from acquisitions, net of divestitures, and a 2% unfavorable foreign-currency effect. Net income margin fell to 16.5% from 18.6%. Adjusted diluted EPS was $2.09, up 7% from $1.96; this non-GAAP measure adds back specified items, including acquisition-related intangible amortization.
Segment results: FMT sales were $321.8 million (+18%) and Adjusted EBITDA $106.2 million (+20%), with margin rising to 33.0%. HST sales were $351.0 million (+11%) and Adjusted EBITDA $100.7 million (+1%); margin declined to 28.7%. FSDP sales were $174.4 million (+6%) and Adjusted EBITDA $49.7 million (+12%); margin increased to 28.5%.
Cash, liquidity and debt
Cash and equivalents were $510.7 million at March 31, versus $430.2 million at year-end 2022. Current assets were $1,524.5 million and current liabilities $491.9 million; management reported a 3.1:1 current ratio and $1,032.6 million of working capital. Operating cash flow benefited from lower working-capital investment than in the prior-year quarter; capital expenditures rose to $26.6 million from $16.1 million.
Total borrowings were $1,479.5 million, including $79.4 million drawn on the revolving facility and $200.0 million on the term facility. The company reported $713.1 million of net available revolver capacity. The $100.0 million of 3.20% notes due June 2023 remained classified as long-term; IDEX said it expected to refinance or repay them using revolver capacity. It was in compliance with debt covenants, reporting a 1.55:1 leverage ratio and 22.48:1 interest coverage ratio. Dividends paid were $45.5 million; there were no Q1 share repurchases.
Changes, outlook and risks
- Growth was broad across segments, but margins contracted overall. Management attributed pressure to unfavorable mix, employee-related inflation and higher costs; acquisitions also diluted consolidated gross margin.
- HST organic sales were affected by customer inventory recalibration and softness in semiconductor, analytical-instrumentation and some life-sciences demand, as well as project delays. Management cited strength in selected scientific-fluidics and pneumatic markets.
- Interest expense rose to $13.1 million from $9.5 million, primarily reflecting borrowings used for the 2022 Muon acquisition. Intangible amortization increased to $23.6 million from $15.3 million.
- No specific full-year financial guidance is provided in the supplied filing text. Management said available cash, operating cash flow and borrowing capacity should cover operating needs, planned capital expenditures, debt service, pension funding and dividends for the foreseeable future.
- On April 25, 2023, IDEX agreed to acquire Iridian Spectral Technologies for C$150 million, subject to customary adjustments and closing conditions; it expected closing by the end of Q2 2023.
- Risks include industrial and economic conditions, inflation and pricing pressure, interest and foreign-exchange rates, supply-chain and labor constraints, acquisition integration, and litigation or other contingencies. The company reported no material changes to its previously disclosed risk factors. It said ordinary-course legal matters, including asbestos claims, were not expected to have a material adverse effect; insurance coverage for asbestos claims may not continue to be available.
Important facts for investors to verify
- Progress and financing of the Iridian acquisition, and integration and returns from recent acquisitions, particularly Muon.
- Repayment or refinancing of the June 2023 notes and the effect of floating-rate debt on interest costs.
- Whether margin pressure, especially in HST, persists and how price, productivity, mix and inflation evolve.
- Cash conversion and working-capital needs, given inventory growth and higher capital expenditures.
- Potential developments in legal proceedings, asbestos insurance coverage and other disclosed contingencies.